BSX vs. ABT, ISRG, SYK, MDT, BDX, EW, DXCM, IDXX, RMD, and STE
Should you be buying Boston Scientific stock or one of its competitors? The main competitors of Boston Scientific include Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), and STERIS (STE). These companies are all part of the "health care equipment" industry.
Abbott Laboratories (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations.
Abbott Laboratories currently has a consensus price target of $120.64, suggesting a potential upside of 12.14%. Boston Scientific has a consensus price target of $76.70, suggesting a potential downside of 0.54%. Given Boston Scientific's higher probable upside, research analysts plainly believe Abbott Laboratories is more favorable than Boston Scientific.
In the previous week, Boston Scientific had 1 more articles in the media than Abbott Laboratories. MarketBeat recorded 18 mentions for Boston Scientific and 17 mentions for Abbott Laboratories. Boston Scientific's average media sentiment score of 0.96 beat Abbott Laboratories' score of 0.78 indicating that Abbott Laboratories is being referred to more favorably in the media.
Abbott Laboratories has higher revenue and earnings than Boston Scientific. Abbott Laboratories is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Abbott Laboratories has a net margin of 13.96% compared to Abbott Laboratories' net margin of 12.06%. Boston Scientific's return on equity of 20.18% beat Abbott Laboratories' return on equity.
Abbott Laboratories has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
Boston Scientific received 81 more outperform votes than Abbott Laboratories when rated by MarketBeat users. However, 69.67% of users gave Abbott Laboratories an outperform vote while only 69.39% of users gave Boston Scientific an outperform vote.
75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 1.1% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.5% of Boston Scientific shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Abbott Laboratories beats Boston Scientific on 10 of the 19 factors compared between the two stocks.
Get Boston Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Boston Scientific Competitors List
Related Companies and Tools
